Gene therapy for uveal melanoma
Gene therapy approaches are under development for uveal melanoma, a blind spot lacking effective treatments where any novel strategy could eventually offer hope.
This review in Clinical & Translational Oncology surveys gene therapy modalities being explored for uveal melanoma—the most common primary intraocular tumour in adults—covering viral vector-based, CRISPR-based, and RNA-interference approaches. The field is early-stage with most work preclinical, but the complete absence of effective systemic therapy for metastatic UM (median OS <1 year) creates strong rationale for any novel approach.
What the study was
- Study design
- narrative_review
- Category
- rare_diseases_unmet_need
- Maturity
- Exploratory
- Journal
- Clinical & Translational Oncology
Why it surfaced
Uveal melanoma is a rare cancer with complete therapeutic failure at metastasis; gene therapy review for an unserved rare cancer warrants pipeline awareness. Score 4 (N=1, D=1, P=2, E=0) for review-level with high unmet need offset.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.